dc.contributor.author |
Ou, Peter |
en |
dc.contributor.author |
Gear, Kim |
en |
dc.contributor.author |
Rahnama, Fahimeh |
en |
dc.contributor.author |
Thomas, Stephen |
en |
dc.contributor.author |
Nagappan, Radhika |
en |
dc.contributor.author |
Kee, Dennis |
en |
dc.contributor.author |
Waldvogel-Thurlow, Sharon |
en |
dc.contributor.author |
Jain, Ravi |
en |
dc.contributor.author |
McIvor, Nick |
en |
dc.contributor.author |
Izzard, Mark |
en |
dc.contributor.author |
Douglas, Richard |
en |
dc.date.accessioned |
2018-10-16T19:31:20Z |
en |
dc.date.issued |
2018-04 |
en |
dc.identifier.issn |
1445-1433 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/41988 |
en |
dc.description.abstract |
BACKGROUND:Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCC) are clinically, epidemiologically and prognostically distinct from other OPSCCs. The incidence of HPV-related OPSCCs has increased significantly worldwide over the past few decades. However, no studies of OPSCC with direct molecular HPV testing has been conducted in New Zealand. AIMS:To estimate the proportion of OPSCCs attributable to HPV infections in a New Zealand population with a validated HPV testing algorithm. METHODS:HPV-status was determined by p16 immunohistochemistry and polymerase chain reaction (PCR) of both L1 and E6/7 genes on 55 OPSCCs diagnosed in 2010 and 2011 in Central and South Auckland. Baseline and survival analyses were performed according to HPV status. RESULTS:Forty-one (75%) of OPSCC tumours had HPV infections. There was 98% concordance between p16 immunohistochemistry and real-time E6/E7 PCR. After a median follow-up period of 2.6 years, patients with OPSCC of HPV aetiology had more favourable outcomes compared to patients with HPV-negative OPSCC (hazard ratio 0.14, P = 0.02) after adjustment for other variables. CONCLUSION:This study highlights the significant role that HPV plays in the aetiology of OPSCC in New Zealand, and confirms the high rate of accuracy of p16 immunostaining. |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
ANZ journal of surgery |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Humans |
en |
dc.subject |
Papillomaviridae |
en |
dc.subject |
Papillomavirus Infections |
en |
dc.subject |
Carcinoma, Squamous Cell |
en |
dc.subject |
Oropharyngeal Neoplasms |
en |
dc.subject |
Incidence |
en |
dc.subject |
Survival Rate |
en |
dc.subject |
Cohort Studies |
en |
dc.subject |
Feasibility Studies |
en |
dc.subject |
Algorithms |
en |
dc.subject |
Adult |
en |
dc.subject |
Aged |
en |
dc.subject |
Middle Aged |
en |
dc.subject |
New Zealand |
en |
dc.subject |
Female |
en |
dc.subject |
Male |
en |
dc.subject |
Cyclin-Dependent Kinase Inhibitor p16 |
en |
dc.subject |
Biomarkers |
en |
dc.title |
Human papillomavirus and oropharyngeal squamous cell carcinoma: a New Zealand cohort study. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1111/ans.13759 |
en |
pubs.issue |
4 |
en |
pubs.begin-page |
E278 |
en |
pubs.volume |
88 |
en |
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
27647686 |
en |
pubs.end-page |
E283 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
542069 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Surgery Department |
en |
dc.identifier.eissn |
1445-2197 |
en |
pubs.record-created-at-source-date |
2016-09-21 |
en |
pubs.dimensions-id |
27647686 |
en |